Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Tobemstomig

Bispecific antibody · Antagonist of PD-1 (PDCD1) and LAG-3 · developed by Hoffmann-La Roche

Phase 1/2 Most advanced trial

1 Registered trials

What is Tobemstomig?

Tobemstomig is a bispecific antibody that binds both PD-1 and LAG-3 on T cells, blocking their immunosuppressive signaling. This restores T-cell activation and proliferation to promote cytotoxic immune responses against tumor cells. It is being studied in advanced liver cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Bispecific antibody
Targets: PD-1 (PDCD1), LAG-3
Mechanism: Antagonist of PD-1 (PDCD1) and LAG-3
Pathways: T-cell activation, immune checkpoint inhibition
Therapy area: Oncology
Developer: Hoffmann-La Roche
In trials of: ADAG
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: 93NRF4S9HR

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04524871	Phase 1/2	Advanced Liver Cancers	Active not recruiting	ADAG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Liver Cancers

Other drugs acting on PDCD1 / LAG3

Berahyaluronidase Alfa and Pembrolizumab FDA approved Nivolumab FDA approved Pembrolizumab FDA approved Relatlimab FDA approved Toripalimab FDA approved Atigotatug/Nivolumab Phase 1 Balstilimab Phase 2/3 BPT567 Phase 1 Budigalimab Phase 2/3 Cadonilimab Early Phase 1 CDX-585 Phase 1 CTX-8371 Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z